Example: barber
Scientific guidelines with SmPC recommendations
Scientific guidelines with SmPC recommendations Table of contents ... treatment of hypertension 4.1, 4.2 Nervous system * Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders Background …
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Hypertension - NHM
nhm.gov.inGUIDELINES Hypertension Screening, Diagnosis, Assessment, and Management of Primary Hypertension in Adults in India Full Background document (Draft) February 2016 Ministry of Health & Family Welfare Government of India 1Screening, Diagnosis, Assessment, and Management of Primary Hypertension- Full Document
2021 ICD-10-CM Guidelines
www.cdc.govICD-10-CM Official Guidelines for Coding and Reporting FY 2021 (October 1, 2020 - September 30, 2021) Narrative changes appear in bold text . Items underlined have been moved within the guidelines since the FY 2020 version
GUIDELINES
www.ayush.gov.inGuidelines, Ayurvedic Pharmacopoeia of India, Ministry of AYUSH Govt. of India along with considerations from other recommendations issued by various health authorities across India. ... health issues such as hypertension, diabetes, cancer-chemotherapy etc. are to be continued.
Your Guide to Lowering Your Blood Pressure with DASH
www.nhlbi.nih.govDietary Guidelines for Americans.” The 1,500 milligram level can lower blood pressure further and more recently is the amount recommended by the Institute of Medicine as an adequate intake level and one that most people should try to achieve. The lower your salt intake is, the lower your blood pressure.
Hypertension medication treatment protocol
www.ama-assn.org1d. See page e194, “Treatment of resistant hypertension … .” 1e. See page e164, for evidence statement. 2. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28. 3. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG.